Navigation Links
Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
Date:4/15/2008

recognize and destroy cancer cells. He has already used these engineered cells in clinical trials for malignant gliomas. In his current clinical protocol, T-cells are removed from a patient with GBM and modified to express the zetakine. These modified cells are infused into the brain following surgery for the targeted elimination of residual tumor cells. Frequently however, glucocorticoids, such as dexamethasone, must be administered to patients pre- and post-surgery to stop the brain-swelling caused by the tumor and surgery. Glucocorticoids inactivate or kill the T-cells through a protein known as the glucocorticoid receptor (GR), limiting the benefit of this novel therapy. Currently, this approach is also patient-specific or autologous, which makes it time and labor-intensive. Cells without a functional GR are drug-resistant and should therefore be available to destroy tumor cells.

The aim of the collaboration is to use Sangamo's zinc finger DNA-binding protein nuclease (ZFN) gene modification technology to delete the GR in T-cells engineered to express the zetakine. The specific deletion of GR in the zetakine-expressing, anti-glioma T-cells allows them to be used in the presence of glucocorticoids and to be developed as an "off the shelf" or allogeneic cell product immediately available to GBM patients. The data presented at AACR suggest that this strategy is effective in animal models of the disease. Sangamo expects to file an Investigative New Drug (IND) application for this cell therapy in 2008.

"These data demonstrate an important direct therapeutic application of our ZFN technology for the optimization of cell-based pharmaceuticals," said Edward Lanphier, Sangamo's president and CEO. "We are very pleased to be working with City of Hope and Mike Jensen and his team who have developed this novel approach to the treatment of GBM. We believe that, in combination with our proprietary ZFN technology, we have the opportunity to significantly broaden t
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
2. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
3. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
4. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
5. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
6. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
7. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
8. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
9. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
10. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
11. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... , May 26, 2015  OrthoAccel ® Technologies, ... its own growth accelerating in response to continued demand ... treatment. Now available in 2,500 practice locations in the ... daily, OrthoAccel,s AcceleDent ® is the only FDA-cleared ... speed up orthodontic treatment by as much as 50 ...
(Date:5/26/2015)... Cellular testing for pharmaceuticals - how ... future of technologies for screening cells? Now discover ... ahead there for data, benefiting your influence. For ... opportunities and revenue forecasts. That new ... possible for cell-based assays and related ...
(Date:5/26/2015)...  BioSpecifics Technologies Corp. (NASDAQ: BSTC ), a ... as XIAFLEX ® in the U.S. and XIAPEX ... President, Tom Wegman , will present a corporate ... The presentation will take place on Monday, ... New York, NY . A live webcast ...
Breaking Medicine Technology:OrthoAccel Technologies Continues Trajectory of Accelerated Growth with Over 2,500 Practice Locations 2OrthoAccel Technologies Continues Trajectory of Accelerated Growth with Over 2,500 Practice Locations 3Cell-Based Assays: World Industry and Market Prospects 2015-2025 2Cell-Based Assays: World Industry and Market Prospects 2015-2025 3Cell-Based Assays: World Industry and Market Prospects 2015-2025 4Cell-Based Assays: World Industry and Market Prospects 2015-2025 5Cell-Based Assays: World Industry and Market Prospects 2015-2025 6Cell-Based Assays: World Industry and Market Prospects 2015-2025 7BioSpecifics Technologies Corp. to Present at the Jefferies 2015 Healthcare Conference 2
... 12 Reportlinker.com announces that a new market ... Active Pharmaceutical Ingredients (APIs) Market ... Biotech Sector will Sustain Growth ... Pharmaceutical Ingredients (APIs) Market to 2015 - Rise ...
... Inc. (Nasdaq: AUXL ), a specialty ... Patent and Trademark Office ("USPTO") issued U.S. Patent ... the active component in Auxilium,s product XIAFLEX® (collagenase ... FOR TREATING COLLAGEN-MEDIATED DISEASES" is expected to expire ...
Cached Medicine Technology:Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 2Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 3Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 4Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 5Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 6Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 7Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 8Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 9Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 10Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 11Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 12Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 13Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 14Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 15Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 16Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 17Auxilium Pharmaceuticals, Inc. Announces Issuance of Patent for Clostridial Collagenase 2Auxilium Pharmaceuticals, Inc. Announces Issuance of Patent for Clostridial Collagenase 3Auxilium Pharmaceuticals, Inc. Announces Issuance of Patent for Clostridial Collagenase 4
(Date:5/27/2015)... 27, 2015 The Advanced Fertility Center of ... open for business to better serve the needs of couples ... Park neighborhood on the Northwest side of the city at ... be arranged by calling the Chicago office at (773) 794–1818. ... Fertility Center of Chicago. The other 2 offices are ...
(Date:5/26/2015)... 27, 2015 Carey Danis & ... testosterone gel lawsuit . The suit pertains to AndroGel, ... was filed in late April 2015, and a court ... Illinois federal court in mid-May.¹ , Testosterone gel lawsuits ... the Northern District of Illinois. The multidistrict litigation (MDL) ...
(Date:5/26/2015)... May 27, 2015 Securityhunter ... (MATOC) by the United States Department of Health and ... The MATOC was awarded through the General ... (FSS) for the PSC, which is a fee-for-service agency. ... one year options, and is an enterprise–wide physical security ...
(Date:5/26/2015)... 2015 Forex Income Boss is a ... their results trading in the foreign exchange market. The ... utilizes 10 customer indicators to help traders locate perfect ... usual, Russ Horn's latest trading system is the talk ... reports Tiffany Hendricks, senior product reviewer at HonestyFirstReview.com. "While ...
(Date:5/26/2015)... Beloved local Arizona company, Parker and Sons, outdoes itself ... guarantee or else its free. , Parker and Sons ... here . What’s more, Parker and Sons offers a customer ... company’s rich legacy, and immense success. , The sixty ... imaginable. Whether it be low water flow or complete clogging, ...
Breaking Medicine News(10 mins):Health News:The Advanced Fertility Center of Chicago Opens a New Fertility Office Location in Chicago 2Health News:Carey Danis & Lowe Comments on Recently Filed Testosterone Gel Lawsuit 2Health News:Securityhunter Has Been Awarded a Multiple Award Task Order Contract (MATOC) by the Department of Health and Human Services 2Health News:Forex Income Boss - Review Of Russ Horn's New FX Trading System Released 2Health News:Parker and Sons Offers Special, Sixty Minute Drain Clean Guarantee or Else It’s on Them 2
... September 3 , - Despite ... Year , Nucletron, a global leader ... half year of 2009. Despite challenging,global economic conditions, Nucletron surpassed ... Net sales amounted to EUR 51.2 million, a 3% growth ...
... , , PHOENIX, Sept. 2 ... southwestern United States, has formed a strategic alliance with American National ... getting claims compensated in a timely manner with a proprietary process ... , , "Over the last 10 years ...
... 2 MedQuist Inc. (Nasdaq: MEDQ ) today ... credit facility. The credit facility provides committed revolving funding ... may increase its maximum credit up to $40 million, based ... a working capital facility that may be used for general ...
... , , ... Liberty Screening Services Ltd.,s new Southeastern U.S. account executive. ... and oversee uniform background-screening strategies for clients throughout the ... Services offers background-screening services for Fortune 500 clients and ...
... BETHESDA, Md., Sept. 2 /PRNewswire-Asia/ -- Chindex ... provider of Western,healthcare products and services in the People,s Republic of ... -- Morgan Stanley Healthcare Corporate Day, to be held ... MA. Management will meet with institutional investors, ...
... , ATLANTA, Sept. 2 /PRNewswire-FirstCall/ ... a leading provider of comprehensive home health services, announced today that ... Magna Home Health), a part of the Rush Health System, located ... from Gentiva,s existing cash reserves. , , "We ...
Cached Medicine News:Health News:Nucletron Increases Full Year Outlook After Strong First Half 2009 2Health News:MedQuist Announces Establishment of Revolving Credit Facility and Payment of Special Cash Dividend 2Health News:Chindex International Announces September Investor Conferences Participation 2Health News:Gentiva(R) Health Services Completes Acquisition of Home Health Agency 2Health News:Gentiva(R) Health Services Completes Acquisition of Home Health Agency 3
A compact mobile System Cart gives mobility within your department. The cart accomodates the Uromac Median data processor, desktop computer, printer and provides stowage space. Patient related transd...
... is ideal for any clinical setting, ... performing a UDS procedure. Customize Delphis™ ... options of a Pocket PC, a ... with Bluetooth™ wireless technology allows you ...
... Designed and manufactured by Laborie, ... equipment. Solenette™ provides credible tracings. ... measurements of true parameters. Designed ... or Medical Professional to be ...
... with ease of use make the OM-5 ... Ideal for office or hospital-based urodynamics, the ... cystometry, leak point pressure, or urethral pressure ... make the OM-5 flexible enough to meet ...
Medicine Products: